These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
158 related articles for article (PubMed ID: 11916363)
1. Apoptosis in cardiovascular remodeling--effect of medication. deBlois D; Orlov SN; Hamet P Cardiovasc Drugs Ther; 2001 Nov; 15(6):539-45. PubMed ID: 11916363 [TBL] [Abstract][Full Text] [Related]
2. JIKEI HEART Study--a morbi-mortality and remodeling study with valsartan in Japanese patients with hypertension and cardiovascular disease. Mochizuki S; Shimizu M; Taniguchi I; Kanae K; Yoshida S; Tajima N; Dahlöf B; Cardiovasc Drugs Ther; 2004 Jul; 18(4):305-9. PubMed ID: 15367828 [TBL] [Abstract][Full Text] [Related]
3. A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation. Paulus WJ; Tschöpe C J Am Coll Cardiol; 2013 Jul; 62(4):263-71. PubMed ID: 23684677 [TBL] [Abstract][Full Text] [Related]
4. Risk factor-induced cardiovascular remodeling and the effects of angiotensin-converting enzyme inhibitors. Galderisi M; de Divitiis O J Cardiovasc Pharmacol; 2008 Jun; 51(6):523-31. PubMed ID: 18520954 [TBL] [Abstract][Full Text] [Related]
8. Cardiovascular remodeling, apoptosis, and drugs. Buemi M; Corica F; Marino D; Medici MA; Aloisi C; Di Pasquale G; Ruello A; Sturiale A; Senatore M; Frisina N Am J Hypertens; 2000 Apr; 13(4 Pt 1):450-4. PubMed ID: 10821351 [TBL] [Abstract][Full Text] [Related]
9. Vascular effects of antihypertensive drug therapy. Rehman A; Schiffrin EL Curr Hypertens Rep; 2010 Aug; 12(4):226-32. PubMed ID: 20514556 [TBL] [Abstract][Full Text] [Related]
10. Proapoptotic and growth-inhibitory role of angiotensin II type 2 receptor in vascular smooth muscle cells of spontaneously hypertensive rats in vivo. Tea BS; Der Sarkissian S; Touyz RM; Hamet P; deBlois D Hypertension; 2000 May; 35(5):1069-73. PubMed ID: 10818066 [TBL] [Abstract][Full Text] [Related]
11. [Hypertension in patients with heart failure]. Takekoshi N; Asaji T; Tada N Nihon Rinsho; 2004 Mar; 62 Suppl 3():478-83. PubMed ID: 15171419 [No Abstract] [Full Text] [Related]
12. Left ventricular remodeling impairs coronary flow reserve in hypertensive patients. Schäfer S; Kelm M; Mingers S; Strauer BE J Hypertens; 2002 Jul; 20(7):1431-7. PubMed ID: 12131541 [TBL] [Abstract][Full Text] [Related]
13. Effects of Xin-Ji-Er-Kang formula on 2K1C-induced hypertension and cardiovascular remodeling in rats. Guo K; Lan CZ; Yu TT; Huang LL; Wang XH; Pan C; Gao S J Ethnopharmacol; 2014 Sep; 155(2):1227-35. PubMed ID: 25063306 [TBL] [Abstract][Full Text] [Related]
14. Effect of antihypertensive treatment on small artery remodeling in hypertension. Schiffrin EL Can J Physiol Pharmacol; 2003 Feb; 81(2):168-76. PubMed ID: 12710531 [TBL] [Abstract][Full Text] [Related]
15. Angiotensin-converting enzyme 2 is a critical determinant of angiotensin II-induced loss of vascular smooth muscle cells and adverse vascular remodeling. Patel VB; Zhong JC; Fan D; Basu R; Morton JS; Parajuli N; McMurtry MS; Davidge ST; Kassiri Z; Oudit GY Hypertension; 2014 Jul; 64(1):157-64. PubMed ID: 24799609 [TBL] [Abstract][Full Text] [Related]
17. [Antihypertensive advantages of angiotensin II AT1 receptor antagonism]. Coca A; Giner V Rev Esp Cardiol; 1999; 52 Suppl 3():53-8. PubMed ID: 10614150 [TBL] [Abstract][Full Text] [Related]
18. Nitric oxide-independent stimulation of soluble guanylate cyclase with BAY 41-2272 in cardiovascular disease. Boerrigter G; Burnett JC Cardiovasc Drug Rev; 2007; 25(1):30-45. PubMed ID: 17445086 [TBL] [Abstract][Full Text] [Related]
19. Advantages of renin-angiotensin system blockade in the treatment of cardiovascular diseases. Gerc V; Buksa M Med Arh; 2010; 64(5):295-9. PubMed ID: 21287956 [TBL] [Abstract][Full Text] [Related]